Drayson MT - Search Results

1

Serum free light chains for monitoring multiple myeloma.

Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Mead GP, et al. Among authors: drayson mt. Br J Haematol. 2004 Aug;126(3):348-54. doi: 10.1111/j.1365-2141.2004.05045.x. Br J Haematol. 2004. PMID: 15257706 Free article.

2

Multiple myeloma.

MacLennan IC, Drayson M, Dunn J. MacLennan IC, et al. BMJ. 1994 Apr 16;308(6935):1033-6. doi: 10.1136/bmj.308.6935.1033. BMJ. 1994. PMID: 8068084 Free PMC article. Review.

3

Glycosylation of polyclonal and paraprotein IgG in multiple myeloma.

Farooq M, Takahashi N, Arrol H, Drayson M, Jefferis R. Farooq M, et al. Glycoconj J. 1997 Jun;14(4):489-92. doi: 10.1023/a:1018555619519. Glycoconj J. 1997. PMID: 9249147

4

MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults.

Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, Maclennan IC. Drayson MT, et al. Br J Haematol. 1998 Apr;101(1):195-202. doi: 10.1046/j.1365-2141.1998.00648.x. Br J Haematol. 1998. PMID: 9576201 Free article. Clinical Trial.

5

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ. Davies FE, et al. J Clin Oncol. 2000 Aug;18(15):2843-51. doi: 10.1200/JCO.2000.18.15.2843. J Clin Oncol. 2000. PMID: 10920132

6

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.

Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, Richards SJ, Drayson M, Smith GM, Selby PJ, Child JA, Morgan GJ. Davies FE, et al. Br J Haematol. 2001 Mar;112(3):814-9. doi: 10.1046/j.1365-2141.2001.02530.x. Br J Haematol. 2001. PMID: 11260088 Free article.

7

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Bradwell AR, et al. Among authors: drayson mt. Clin Chem. 2001 Apr;47(4):673-80. Clin Chem. 2001. PMID: 11274017 Clinical Trial.

8

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Drayson M, et al. Blood. 2001 May 1;97(9):2900-2. doi: 10.1182/blood.v97.9.2900. Blood. 2001. PMID: 11313287 Free article.

9

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma.

McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. McCloskey EV, et al. Among authors: drayson mt. Br J Haematol. 2001 Jun;113(4):1035-43. doi: 10.1046/j.1365-2141.2001.02851.x. Br J Haematol. 2001. PMID: 11442499 Free article. Clinical Trial.

10

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Rawstron AC, et al. Among authors: drayson mt. Blood. 2002 Nov 1;100(9):3095-100. doi: 10.1182/blood-2001-12-0297. Blood. 2002. PMID: 12384404 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page